Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - il-prodotti terapewtiċi l-oħra kollha - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - sucroferric oxyhydroxide - hyperphosphatemia; renal dialysis - - mediċini għal-kura tal-iperkalimja u ' l-iperphosphatemija - velphoro huwa indikat għall-kontroll ta 'livelli ta' fosfru fis-serum f'pazjenti b'mard tal-kliewi kroniku adulti (ckd) fuq emodijaliżi (hd) jew dijalisi peritoneali (pd). velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with ckd stages 4-5 (defined by a glomerular filtration rate.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

bial - portela cª, s.a. - opicapone - marda ta 'parkinson - mediċini kontra l-parkinson - ongentys huwa indikat bħala terapija adjunctive għall-preparazzjonijiet ta ' ticlopidine hydrochloride / dopa decarboxylase inibituri (ddci) fil-pazjenti adulti mal-marda ta ' parkinson's u l-tmiem tad-doża oxxillazzjonijiet vetturi bil-mutur li ma tistax tiġi stabilizzata fuq dawk l-għaqdiet. ongentys huwa indikat bħala terapija adjunctive għall-preparazzjonijiet ta ' ticlopidine hydrochloride / dopa decarboxylase inibituri (ddci) fil-pazjenti adulti mal-marda ta ' parkinson's u l-tmiem tad-doża oxxillazzjonijiet vetturi bil-mutur li ma tistax tiġi stabilizzata fuq dawk l-għaqdiet.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - patiromer sorbitex calcium - iperkalemija - - mediċini għal-kura tal-iperkalimja u ' l-iperphosphatemija - veltassa huwa indikat għall-kura ta 'iperkalimja fl-adulti.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

sandoz gmbh - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone - mediċini għall-kura ta'mard fl-għadam, bisphosphonates - sandoz aċidu ibandronic huwa indikat għall-prevenzjoni ta ' l-iskeletru avvenimenti (fratturi patoloġiċi, għadam komplikazzjonijiet li jeħtieġu radjoterapija jew kirurġija) fil-pazjenti bl-metastaΩi tal-kanċer u l-għadma tas-sider.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, fluticasone propionate - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

teva b.v. - fluticasone propionate, salmeterol xinafoate - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - aerivio spiromax huwa indikat għall-użu f'adulti li għandhom 18-il sena 'l fuq biss. asthmaaerivio spiromax huwa indikat għat-trattament regolari ta 'pazjenti b'ażżma severa fejn l-użu tal-kombinazzjoni tal-prodott (kortikosterojdi meħuda man-nifs u li jaħdem fit-tul β2 agonist) huwa xieraq:pazjenti li mhumiex kontrollati sew dwar l-qawwa l-baxxa ta'kortikosterojdi kombinazzjoni-prodott orpatients diġà ikkontrollati fuq doża għolja ta' kortikosterojdi meħuda man-nifs u li jaħdem fit-tul β2 agonist. mard pulmonari ostruttiv kroniku (copd)aerivio spiromax huwa indikat għall-kura sintomatika ta ' pazjenti b'copd, bil-fev1.

Ευρωπαϊκή Ένωση - Μαλτεζικά - EMA (European Medicines Agency)

teva b.v. - salmeterol, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - airexar spiromax huwa indikat għall-użu fl-adulti li għandhom 18-il sena 'l fuq biss. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. mard pulmonari ostruttiv kroniku (copd)airexar spiromax huwa indikat għall-kura sintomatika ta ' pazjenti b'copd, bil-fev1.